

Item 2.02.

Results of Operations and Financial Condition.

On November 10, 2008, Keryx Biopharmaceuticals, Inc. (“Keryx”) issued a press release announcing results of operations for the third quarter ended September 30, 2008, and announced that it would host a conference call on November 11, 2008, for investors where Keryx will discuss its results of operations and financial results. A copy of the press release is being furnished as Exhibit 99.1 to this report.

Item 8.01.

Other Events.

On November 10, 2008, Keryx issued a press release announcing that data from its Phase I/II clinical trial of KRX-0401 (perifosine) has been selected for oral presentation at the upcoming 50th Annual Meeting of the American Society of Hematology (“ASH”), to be held in San Francisco beginning December, 2008. A copy of this press release is being furnished as Exhibit 99.2 to this report, and the abstract of the study is being furnished as Exhibit 99.3 to this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Keryx Biopharmaceuticals, Inc.
(Registrant)

Date: November 10, 2008

By: /s/ James F. Oliviero

James F. Oliviero
Vice President, Finance

INDEX TO EXHIBITS

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated November 10, 2008.
99.2	Press Release dated November 10, 2008.
99.3	Abstract of Study Entitled “Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib.”
